The Role of Tumor Mutational Burden in Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Related Videos

August 15, 2016

Carcinoid Heart Disease

Richard Parker, MD, provides an overview of this condition, which is common on patients with carcinoid syndrome. 

October 6, 2014

Managing and Navigating Patients with Polycythemia Vera

Emily A. Knight, RN of the Mayo Clinic in Scottsdale, AZ, describes issues faced in managing and navigating patients with polycythemia Supported through funding from Incyte